Current vascular pharmacology最新文献_第8页

Benefits of Statins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitors for Patients with Peripheral Arterial Disease. 他汀类药物和蛋白转化酶枯草杆菌素/可欣9型(PCSK-9)抑制剂对外周动脉疾病患者的益处

IF 4.5 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611292747231129080204

Kosmas I Paraskevas, Debabrata Mukherjee, Theofanis T Papas

引用次数: 0

Assessment of Early Vascular Aging Ambulatory Score (EVAAs): A Large Population-based External Validation Study. 早期血管老化门诊评分（EVAAs）评估：大型人群外部验证研究》。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611299635240708045352

Christina Antza, Victoria Potoupni, Evangelos Akrivos, Stella Stabouli, Vasilios Kotsis

{"title":"Assessment of Early Vascular Aging Ambulatory Score (EVAAs): A Large Population-based External Validation Study.","authors":"Christina Antza, Victoria Potoupni, Evangelos Akrivos, Stella Stabouli, Vasilios Kotsis","doi":"10.2174/0115701611299635240708045352","DOIUrl":"10.2174/0115701611299635240708045352","url":null,"abstract":"Background: Pulse Wave Velocity (PWV) remains the gold-standard method to assess Early Vascular Aging (EVA) defined by arterial stiffness. However, its high cost, time-consuming process, and need for qualified medical staff shows the importance of identifying alternative methods for the EVA evaluation.Objective: In order to simplify the process of assessing patient's EVA, we recently developed the Early Vascular Aging Ambulatory score (EVAAs), a simple tool to predict the risk of EVA. The aim of the present study was the external validation of EVAAs in an independent population.Methods: Eight hundred seventy-nine (46.3% men) patients who were referred to our Hypertension ESH Excellence Center were included in this study. The mean age was 46.43 ± 22.87 years. EVA was evaluated in two different ways. The first assessment included c-f PWV values, whereas the second one included EVAAs without the direct measurement of carotid-femoral PWV.Results: The null hypothesis was that the prediction of EVA based on EVAAs does not present any statistically significant difference compared to the prediction based on the calculation from c-f PWV. Mean squared error (MSE) was used for the assessment of the null hypothesis, which was found to be 0.40. The results revealed that the EVAAs shows the probability of EVA with 0.98 sensitivity and 0.75 specificity. The EVAAs present 95% positive predictive value and 92% negative predictive value.Conclusion: Our study revealed that EVAAs could be as reliable as the carotid-femoral PWV to identify patients with EVA. Hence, we hope that EVAAs will be a useful tool in clinical practice.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"417-425"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peripheral Arterial Disease: An Underestimated Aspect of Menopause-related Cardiovascular Disease. 外周动脉疾病：与更年期有关的心血管疾病中被低估的一个方面

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611295374231212110458

Panagiotis Anagnostis, Dimitri P Mikhailidis, Ales Blinc, Mojca Jensterle, Mateja K Ježovnik, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Sabovic, Pavel Poredos

引用次数: 0

Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess. 内分泌紊乱和外周动脉疾病——库欣综合征-皮质醇过量的一系列综述。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611272145231106053914

P Poredoš, G H Schernthaner, A Blinc, D P Mikhailidis, M Jensterle, P Anagnostis, P L Antignani, K Bajuk Studen, M Šabović, M K Ježovnik

引用次数: 0

Antiplatelet Effect of Low-Dose Prasugrel in Elderly Patients Undergoing Percutaneous Coronary Interventions. 小剂量普拉格雷对接受经皮冠状动脉介入治疗的老年患者的抗血小板作用

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611280276240529105022

Monica Verdoia, Matteo Nardin, Rocco Gioscia, Andrea Rognoni, Giuseppe De Luca

{"title":"Antiplatelet Effect of Low-Dose Prasugrel in Elderly Patients Undergoing Percutaneous Coronary Interventions.","authors":"Monica Verdoia, Matteo Nardin, Rocco Gioscia, Andrea Rognoni, Giuseppe De Luca","doi":"10.2174/0115701611280276240529105022","DOIUrl":"10.2174/0115701611280276240529105022","url":null,"abstract":"Background: Low-dose prasugrel (5 mg) has been proposed for patients with Acute Coronary Syndrome (ACS) and advanced age or low body weight. However, the routine use of dose-adjusted prasugrel in this high-risk subset of patients is still debated.Aim: This study aimed to assess the prevalence and predictors of HRPR among elderly patients treated with low-dose (5 mg) prasugrel to evaluate the routine use of dose-adjusted prasugrel in this high-risk subset of patients.Methods: We included 59 elderly patients (≥75 years) treated with Dual Antiplatelet Therapy (DAPT: acetylsalicylic acid (ASA) 100-160 mg + prasugrel 5 mg) after Percutaneous Coronary Interventions (PCI) and undergoing platelet function assessment (by whole blood impedance aggregometry) 30-90 days post-discharge.Results: At a median follow-up of 43 days (interquartile range-IQR: 32-54), high-on treatment residual platelet reactivity (HRPR) occurred in 25 patients (42.4%), who displayed a greater body mass index (BMI) (p=0.02), lower levels of vitamin D (p=0.05) and were more frequently treated with nitrates (p=0.03). After multivariate analysis, BMI was the only independent predictor of prasugrel HRPR, and a BMI >26 was the best cut-off for predicting HRPR (adjusted Odds Ratio - OR=8.6, 95%CI: 2.2-33.9, p=0.002).Conclusion: Among elderly patients receiving DAPT after PCI, HRPR is common with low-dose prasugrel. A greater BMI, especially for values ≥26, is the only independent predictor of HRPR with prasugrel 5 mg.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"335-341"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention. 替罗非班对接受初次经皮冠状动脉介入治疗的急性心肌梗死和糖尿病患者的影响。

IF 4.5 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611251882231012080210

Xiuying Tang, Runjun Li

{"title":"Effects of Tirofiban in Patients with Acute Myocardial Infarction and Diabetes Mellitus undergoing Primary Percutaneous Coronary Intervention.","authors":"Xiuying Tang, Runjun Li","doi":"10.2174/0115701611251882231012080210","DOIUrl":"10.2174/0115701611251882231012080210","url":null,"abstract":"Objective: This study evaluated the efficacy and safety of early vs. late tirofiban administration in the treatment of patients with acute ST-elevation myocardial infarction (STEMI) and diabetes mellitus (DM) undergoing primary percutaneous coronary intervention (pPCI).Methods: 120 patients with STEMI and DM treated with pPCI were randomly divided into an observation group (n=60) and a control group (n=60). The observation group and the control group were intravenously injected with a bolus of tirofiban preoperatively or intraoperatively, respectively; both groups were then given an intravenous infusion over 24 h at 0.15 μg/kg/min. Thrombolysis in myocardial infarction (TIMI) grade flow, myocardial perfusion index, and functional heart parameters, as well as major adverse cardiovascular events and bleeding, were compared between the two groups.Results: Functional heart parameters, including left ventricular ejection fraction and cardiac output, were significantly improved in the observation group 6 months after discharge. Thrombus aspiration, inflammatory factors, and cardiac troponin I (cTNI) were more significantly decreased in the observation group than in the control group. The sum-ST-segment elevation at 2 h after pPCI treatment in the observation group was better than that in the control group. There was no significant difference in the incidence of adverse reactions and bleeding between the two groups.Conclusion: The administration of tirofiban before reperfusion therapy compared with after reperfusion therapy is more effective in reducing the hyperthrombotic load, thrombus aspiration, inflammatory factors, and cTNI and can effectively improve myocardial perfusion and heart function.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"41-49"},"PeriodicalIF":4.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of Vascular Genes Differentially Expressed in the Brain of Patients with Alzheimer's Disease. 识别阿尔茨海默病患者大脑中不同表达的血管基因

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611298073240612050741

Kevins Jara-Medina, Luis Lillo, Constanza Lagunas, Gerardo Cabello-Guzmán, Francisco J Valenzuela-Melgarejo

{"title":"Identification of Vascular Genes Differentially Expressed in the Brain of Patients with Alzheimer's Disease.","authors":"Kevins Jara-Medina, Luis Lillo, Constanza Lagunas, Gerardo Cabello-Guzmán, Francisco J Valenzuela-Melgarejo","doi":"10.2174/0115701611298073240612050741","DOIUrl":"10.2174/0115701611298073240612050741","url":null,"abstract":"Background: Alzheimer's disease (AD) plays a prominent role as the most common form of dementia. Moreover, the traditional mechanism of AD does not explain the microvascular damage observed in about 25-30 years between the onset of AD, which results in late application treatment that inhibits or delays neurodegeneration.Objective: Our objective was to identify differentially expressed genes in human brain samples associated with vascular disruption in AD.Methods: We analyzed 1633 post-mortem brain samples in the GEO database and, after applying clinical and bioinformatic exclusion criteria, worked with 581 prefrontal and frontal samples. All datasets were analyzed using GEO2R from NCBI. We identified common genes using the Venny tool, and their metabolic relevance associated with AD and the vascular system was analyzed using MetaboAnalyst tools.Results: Our bioinformatic analysis identified PRKCB, MAP2K2, ADCY1, GNA11, GNAQ, PRKACB, KCNMB4, CALD1, and GNAS as potentially involved in AD pathogenesis. These genes are associated with signal transductions, cell death signaling, and cytoskeleton, suggesting potential modulation of cellular physiology, including endoplasmic reticulum and mitochondrial activity.Conclusion: This study generates hypotheses regarding the roles of novel genes over critical pathways relevant to AD and its relation with vascular dysfunction. These findings suggest potential new targets for further investigation into the pathogenesis of dementia and AD.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"404-416"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension. 肺动脉高压的药理作用和潜在新疗法。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611266576231211045731

Renata Trabach Santos, Maria Eduarda de Sá Freire Onofre, Dayene de Assis Fernandes Caldeira, Adriane Bello Klein, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz, Pedro Leme Silva

引用次数: 0

P2Y₁₂ Inhibitor or Aspirin Monotherapy in Patients with Coronary Artery Disease: is it Time for a Paradigm Shift? 冠状动脉疾病患者P2Y12抑制剂或阿司匹林单药治疗:是时候进行范式转变了吗?

IF 4.5 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611269735231106110250

Felice Gragnano, Antonio Capolongo, Paolo Calabrò

引用次数: 0

Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention. -受体阻滞剂在高血压左室肥厚和房颤预防中的作用。

IF 4.5 3区医学

Current vascular pharmacology Pub Date : 2024-01-01 DOI: 10.2174/0115701611264647231110101700

Goran Koraćević, Sladjana Mićić, Milovan Stojanović, Marija Zdravkovic, Dragan Simić, Tomislav Kostić, Vesna Atanasković, Ružica Janković-Tomašević

{"title":"Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention.","authors":"Goran Koraćević, Sladjana Mićić, Milovan Stojanović, Marija Zdravkovic, Dragan Simić, Tomislav Kostić, Vesna Atanasković, Ružica Janković-Tomašević","doi":"10.2174/0115701611264647231110101700","DOIUrl":"10.2174/0115701611264647231110101700","url":null,"abstract":"Background: Hypertensive left ventricular hypertrophy (HTN LVH) is a key risk factor for atrial fibrillation (AF).Objective: To evaluate the possible role of beta-blockers (BBs) in addition to a renin-angiotensinaldosterone system (RAAS) blocker in AF prevention in patients with HTN LVH.Methods: We performed a PubMed, Elsevier, SAGE, Oxford, and Google Scholar search with the search items 'beta blocker hypertension left ventricular hypertrophy patient' from 2013-2023. In the end, a 'snowball search', based on the references of relevant papers as well as from papers that cited them was performed.Results: HTN LVH is a risk factor for AF. In turn, AF substantially complicates HTN LVH and contributes to the genesis of heart failure (HF) with preserved ejection fraction (HFpEF). The prognosis of HFpEF is comparable with that of HF with reduced EF (HFrEF), and, regardless of the type, HF is associated with five-year mortality of 50-75%. The antiarrhythmic properties of BBs are wellrecognized, and BBs as a class of drugs are - in general - recommended to decrease the incidence of AF in HTN.Conclusion: BBs are recommended (as a class) for AF prevention in several contemporary guidelines for HTN. LVH regression in HTN - used as a single criterion for the choice of antihypertensive medication - does not capture this protective effect. Consequently, it is worth studying how meaningful this antiarrhythmic action (to prevent AF) of BBs is in patients with HTN LVH in addition to a RAAS blocker.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"19-27"},"PeriodicalIF":4.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0